Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 20;13(3):835.
doi: 10.3390/life13030835.

Interventional Radiology in the Treatment of Pancreatic Adenocarcinoma: Present and Future Perspectives

Affiliations
Review

Interventional Radiology in the Treatment of Pancreatic Adenocarcinoma: Present and Future Perspectives

Ernesto Punzi et al. Life (Basel). .

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease; patients' long-term survival is strictly linked to the surgical resection of the tumor but only a minority of patients (2-3%) have a resectable disease at diagnosis. In patients with surgically unresectable disease, interventional radiology is taking on an increasing role in treatment with the application of loco-regional percutaneous therapies. The primary purposes of this narrative review are to analyze the safety and efficacy of ablative techniques in the management of borderline resectable and locally advanced diseases and to underline the role of the interventional radiologist in the management of patients with distant metastases. The secondary purpose is to focus on the synergy between immunotherapy and ablative therapies.

Keywords: immunotherapy; irreversible electroporation; liver metastases chemoembolization; pancreatic adenocarcinoma; thermal ablation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
CT scan shows correct placement of the 4 electrodes (19 G) at the periphery of the pancreatic head tumor (interelectrode distance < 20 mm and angulation < 10°).

References

    1. Vernuccio F., Messina C., Merz V., Cannella R., Midiri M. Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: Role of the Radiologist and Oncologist in the Era of Precision Medicine. Diagnostics. 2021;11:2166. doi: 10.3390/diagnostics11112166. - DOI - PMC - PubMed
    1. Filson A., Gaskins J.T., Martin R.C. A meta-analysis and systematic review of intraoperative bile cultures association with postoperative complications in pancreaticoduodenectomy. Surgery. 2023 doi: 10.1016/j.surg.2022.12.012. - DOI - PMC - PubMed
    1. Tempero M.A., Malafa M.P., Al-Hawary M., Behrman S.W., Benson A.B., III, Cardin D.B., Chiorean E.G., Chung V., Czito B., Chiaro M.B., et al. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. 2021;19:439–457. doi: 10.6004/jnccn.2021.0017. - DOI - PubMed
    1. Mizrahi J.D., Surana R., Valle J.W., Shroff R.T. Pancreatic cancesr. Lancet. 2020;395:2008–2020. doi: 10.1016/S0140-6736(20)30974-0. - DOI - PubMed
    1. Ducreux M., Cuhna A.S., Caramella C., Hollebecque A., Burtin P., Goéré D., Seufferlein T., Haustermans K., Van Laethem J.L., Conroy T., et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2015;26((Suppl. S5)):v56–v68. doi: 10.1093/annonc/mdv295. - DOI - PubMed

LinkOut - more resources